Pathology of GM2 gangliosidosis in Jacob sheep

Veterinary Pathology

Volumn 48, Issue 4, 2011, Pages 807-813

  Porter, Brian F ^a   Lewis, B C ^b   Edwards, J F ^a   Alroy, J ^c   Zeng, B J ^d   Torres, P A ^d   Bretzlaff, K N ^a   Kolodny, E H ^d  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY SYSTEM   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GM2 gangliosidosis; hexosaminidases; lysosomal storage diseases; sheep; Tay Sachs disease

Indexed keywords

ANIMALIA; OVIS ARIES;

ANIMAL; ANIMAL DISEASE; ARTICLE; BRAIN; CASE REPORT; CEREBELLUM; CYTOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; GM2 GANGLIOSIDOSIS; MALE; PATHOLOGY; SHEEP; SHEEP DISEASE; SPINAL CORD;

ANIMALS; CEREBELLUM; CEREBRUM; FEMALE; GANGLIOSIDOSES, GM2; GENE EXPRESSION REGULATION; MALE; SHEEP; SHEEP DISEASES; SPINAL CORD;

EID: 79959798936     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1177/0300985810388522     Document Type: Article

References (49)

1. Aronson SM.The pathology of Tay-Sachs' disease.Bull N Y Acad Med. 1954;30 (1): 72-4.
2. M2-gangliosidosis. Acta Neuropathol. 1970;16 (3): 243-61.
3. Boomkamp SD,Butters TD.Glycosphingolipid disorders of the brain.Subcell Biochem. 2008;49:441-67.
4. Bradbury AM,Morrison NE,Hwang M, et al.Neurodegenerative lysosomal storage disease in European Burmese cats with hexosaminidase beta-subunit deficiency.Mol Genet Metab. 2009;97 (1): 53-9.
5. Cachón-González MB,Wang SZ,Lynch A, et al.Effective gene therapy in an authentic model of Tay-Sachs-related diseases.Proc Natl Acad Sci. 2006;103 (27): 10373-8.
6. Cohen-Tannoudji M,Marchand P, et al.Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease.Mamm Genome. 1995;6 (12): 844-9.
7. M2 gangliosidosis.Am J Pathol. 1978;90 (3): 723-34.
8. M2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency.Science. 1977;196 (4293): 1014-7.
9. M2 gangliosidosis in a Japanese spaniel.Acta Neuropathol. 1985;67 (3-4): 247-53.
10. Folkerth RD.Abnormalities of developing white matter in lysosomal storage diseases.J Neuropathol Exp Neurol. 1999;58 (9): 887-902.
11. Folkerth RD,Alroy J,Bhan I, et al.Infantile GM1 gangliosidosis: complete morphology and histochemistry of two autopsy cases, with particular reference to delayed central nervous system myelination.Pediatr Dev Pathol. 2000;3 (1): 73-86.
12. M2 gangliosidosis).Acta Neuropathol. 1999;97 (1): 57-62.
13. Gieselmann V.What can cell biology tell us about heterogeneity in lysosomal storage diseases?.Acta Pediatr. 2005;94 (447): 80-6.
14. Goebel HH.Morphology of the gangliosidoses.Neuropediatrics. 1984;15 (Suppl): 97-106.
15. M2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.Hum Mol Genet. 1997;6 (11): 1879-85.
16. Jeyakumar M,Butters TD,Dwek RA, et al.Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.Neuropathol Appl Neurobiol. 2002;28 (5): 343-57.
17. M2 gangliosidosis.Brain. 2003;126 (Pt 4): 974-87.
18. M2-gangliosidoses (amaurotic idiocies) types I.II, and 3. Am J Pathol. 1973;71 (1): 151-4.
19. M2 gangliosidosis.J Neurochem. 2009;111 (4): 1031-41.
20. Kolodny EH.Molecular genetics of the β-hexosaminidase isoenzymes: an introduction.Adv Genet. 2001;44:101-26.
21. M2 gangliosidosis.Acta Neuropathol. 2005;110 (5): 443-50.
22. M2-gangliosidosis (Sandhoff's disease) in Korat cats.J Clin Invest. 1985;76 (2): 482-90.
23. Pelled D,Lloyd-Evans E,Riebeling C, et al.Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.J Biol Chem. 2003;278 (32): 29496-501.
24. Phaneuf D,Wakamatsu N,Huang JQ, et al.Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.Hum Mol Genet. 1996;5 (1): 1-14.
25. M2 gangliosidosis).Am J Pathol. 1976;83 (2): 419-22.
26. Purpura DP,Suzuki K.Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease.Brain Res. 1976;116 (1): 1-21.
27. M2 gangliosidosis: past experiences, implications, and future prospects.Adv Genet. 2001;44:317-39.
28. Read WK,Bridges CH.Cerebrospinal lipodystrophy in swine: a new disease model in comparative pathology.Pathol Vet. 1968;5 (1): 67-74.
29. Roizin L, Kaufman MA: Dyslipidoses. In: Pathology of the Nervous System, ed. Minckler J, pp. 1286-91. McGraw-Hill, New York, NY, 1971.
30. Sabourdy F,Kedjouar B,Sorli SC, et al.Functions of sphingolipid metabolism in mammals-lessons from genetic defects.Biochim Biophys Acta. 2008;1781 (4): 145-83.
31. Sango K,Yamanaka S,Hoffmann A, et al.Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.Nat Genet. 1995;11 (2): 170-6.
32. M2 gangliosidosis: morphological and biochemical analysis.Vet Pathol. 1989;26 (2): 114-20.
33. Suzuki K, Suzuki K: Lysosomal diseases. In: Greenfield's Neuropathology, ed. Graham DI and Lantos PL, 7th ed., pp. 654-64. Arnold, London, 2002.
34. Taniike M,Yamanaka S,Proia RL, et al.Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease.Acta Neuropathol. 1995;89 (4): 296-304.
35. Tessitore A, del P Martin M, Sano R, et al: GM1-gangliosidemediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell 15(5):753-66, 2004.
36. Torres PA, Zeng BJ, Porter BF, Alroy A, Horak F, Horak J, Kolodny EH: Tay-Sachs disease in Jacob sheep. Mol Genet Metab. doi:10.1016/j.ymgme.2010.08.006.
37. van der Voorn JP,Kamphorst W,van der Knaap MS, et al.The leukoencephalopathy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction.Acta Neuropathol. 2004;107 (6): 539-45.
38. Volk BW,Adachi M,Schneck L.The gangliosidoses.Hum Pathol. 1975;6 (5): 555-69.
39. VolkBW, Schneck L, AdachiM: Clinic, pathology and biochemistry of Tay-Sachs disease. In: Handbook of Clinical Neurology, ed. Vinken PJ and Bruyn GW, pp. 385-426. North-Holland, Amsterdam, 1970.
40. Wada R,Tifft CJ,Proia RL.Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.Proc Natl Acad Sci U S A. 2000;97 (20): 10954-9.
41. Walkley SU.Cellular pathology of lysosomal storage disorders.Brain Pathol. 1998;8 (1): 175-93.
42. Walkley SU.Secondary accumulation of gangliosides in lysosomal storage disorders.Semin Cell Dev Biol. 2004;15 (4): 433-44.
43. Walkley SU,Zervas M,Wiseman S.Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons.Cereb Cortex. 2000;10 (10): 1028-37.
44. Wu YP,Mizugishi K,Bektas M.Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease.Hum Mol Genet. 2008;17 (15): 2257-64.
45. Wu YP,Proia RL.Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice.Proc Natl Acad Sci U S A. 2004;101 (22): 8425-30.
46. Yamanaka S,Johnson MD,Grinberg A, et al.Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease.Proc Natl Acad Sci U S A. 1994;91 (21): 9975-9.
47. Yamato O,Matsuki N,Satoh H, et al.Sandhoff disease in a golden retriever dog.J Inherit Metab Dis. 2002;25 (4): 319-20.
48. M2-gangliosidosis variant 0 (Sandhoff-like disease) in a family of Japanese domestic cats.Vet Rec. 2004;155 (23): 739-44.
49. Zeng BJ,Torres PA,Viner TC, et al.Spontaneous appearance of Tay-Sachs disease in an animal model.Mol Genet Metab. 2008;95 (1-2): 59-65.